Previous Close | 66.02 |
Open | 0.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's Range | 66.02 - 66.02 |
52 Week Range | 66.02 - 66.02 |
Volume | |
Avg. Volume | N/A |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
The GSK group posted an 18% rise in sales to £7.8bn over the third quarter.
Jay Powell sounded hawkish on the outlook for rate rises from the central bank.
The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants. Tuesday's news came days after shares of GlaxoSmithKline Plc, Sanofi SA, Pfizer Inc and Haleon Plc were hit by mounting investor concern about thousands of lawsuits claiming the drug, which U.S. regulators pulled from the market in 2020, causes cancer. The plaintiff, Joseph Bayer, alleged he developed esophageal cancer from taking over-the-counter Zantac.